Riverhead Capital Management’s Anika Therapeutics ANIK Stock Holding History

Riverhead Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$110K	Buy	+2,000	New	+$103K	﹤0.01%	1307

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Riverhead Capital Management's ANIK Position: Q3 2019 in Review

Riverhead Capital Management opened a new position in Anika Therapeutics (ANIK) in Q3 2019: 2,000 shares worth $110K. The stake represents ﹤0.01% of the portfolio and ranks #1307 among its holdings.

194 funds tracked by Wall St. Rank hold ANIK as of Q3 2019.

Riverhead Capital Management held 2,000 shares of Anika Therapeutics worth $110K as of Q3 2019.
Anika Therapeutics was a new Riverhead Capital Management position in Q3 2019.
Anika Therapeutics made up ﹤0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #1307 holding.
194 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.